Tuesday, 13 May 2025
This website uses cookies. By using our site you agree to our privacy policy
Username:
Password:
Lost username/password
Create an account
  • Home
  • About Us
    • Accreditation
    • Contact Us
  • Newsletters
  • Continuing Education
    • Diffuse Large B-cell Lymphoma
    • Follicular Lymphoma
    • CLL in Rural America
    • Multidisciplinary Perspectives on BTK Inhibitors Adverse Events Management in CLL and MCL

Andreas Engert, MD

Professor of Internal Medicine, Hematology, and Oncology
University Clinic of Cologne
Cologne, Germany
Last modified: November 26, 2018
Authored Items
Case Study of a Newly Diagnosed HL Patient: The Role of CD30 from Diagnosis to Treatment
Andreas Engert, MD
Case Discussion published on May 17, 2016
An Overview of New Trials in HL
Andreas Engert, MD
Clinical Expert Commentaries published on November 19, 2014
International Guidelines on Follow-Up and Survivorship
Andreas Engert, MD
EHA 2014: Meeting Highlights in Hodgkin Lymphoma published on July 16, 2014
How much of a concern is secondary acute leukemia and myelodysplasia after BEACOPP escalated?
Andreas Engert, MD
FAQ published on March 5, 2014
What is the HD15 trial and how will it affect the treatment of patients with advanced-stage Hodgkin lymphoma?
Andreas Engert, MD
Clinical Trial Highlights published on February 18, 2014
What are the key management guidelines for treating Hodgkin lymphoma?
Andreas Engert, MD
FAQ published on January 15, 2014
Overview of the 9th ISHL 2013
Andreas Engert, MD
9th ISHL Highlights media published on November 4, 2013

MediCom Worldwide, Inc. Links

ManagingAML.com | ManagingMyeloma.com | ManagingMDS.com | ManagingMPN.com | PracticalOncologist.com | PracticalHematologist.com | ManagingCVD.com | ManagingSCD.com | MediComWorldwide.com

©2025 MediCom Worldwide, Inc. All rights reserved

  • Privacy, Terms, and Conditions
  • Contact Us